FDA CONFIRMS TARGET DECISION DATE FOR NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION)

Sep 05, 2018
PDF Version
Supporting Materials:

Theratechnologies Inc. (“Theratechnologies”) (TSX: TH) today announced that the Food and Drug Administration (“FDA”) has set the target date to November 3, 2018 to issue a decision on the supplemental New Drug Application (sNDA) filed on July 3, 2018 regarding the commercialization of a new singlevial formulation of EGRIFTA®.